Shanghai Bio-heart Biological Technology Co., Ltd. (2185) reported that its subsidiary, Shanghai AngioCare Medical Technology Co., Ltd., recently completed the first commercial procedure using the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) in Switzerland. The procedure took place at the University Hospital Basel with no complications or adverse events reported, supported jointly by Biosensors International Group, Ltd. and AngioCare.

AngioCare and Biosensors have a strategic partnership covering multiple regions, including the European Union, the Asia–Pacific region, and Latin America, for the commercialization of the Iberis® RDN system. According to the announcement, this system is currently the only renal denervation product approved globally with both transradial (TRA) and transfemoral (TFA) approaches.

Biosensors is a Bermuda-incorporated company under the cardiovascular and cerebrovascular business division of Bule Sail Medical Co., Ltd. (002382), operating worldwide with headquarters in Singapore and a European office in Morges, Switzerland.

The announcement also states that there is no guarantee Iberis® RDN system will be ultimately developed or marketed successfully, and investors are advised to exercise due care when dealing in the shares of Shanghai Bio-heart Biological Technology Co., Ltd.